Phibro Animal Health: The Animal Is Unleashed
Phibro Animal Health's acquisition of Zoetis' medicated feed additive business has driven significant momentum and improved financial performance. Organic growth and margin expansion is seen across all segments, not just from the Zoetis deal, signaling a real operational turnaround. Despite a 50% share price rally, the stock remains attractively valued at a low double-digit earnings multiple, with manageable leverage.
Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights
Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.
Here's Why Zoetis (ZTS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) reached $168.82 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript)
Zoetis Inc. (NYSE:ZTS ) William Blair 45th Annual Growth Stock Conference June 3, 2025 11:40 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Brandon Vazquez - William Blair Brandon Vazquez Right. Good morning, everyone.
Zoetis Inc. (ZTS) Stifel 2025 Jaws & Paws Conference (Transcript)
Zoetis Inc. (NYSE:ZTS ) Stifel 2025 Jaws & Paws Conference May 29, 2025 9:10 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Jon Block - Stifel Jon Block Great. Thank you.
Zoetis (ZTS) Upgraded to Buy: Here's Why
Zoetis (ZTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Zoetis (ZTS) Could Surge 26.18%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zoetis' Q1: Market Overreaction Or Justified Drop?
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of how consistent buybacks can become significant over long periods. Despite competitive pressures, key franchises like Simparica and Apoquel continue to grow. This portrays one of the attractive characteristics of the animal health industry.
